People Using GLP-1s, Like Ozempic, Wegovy, Less Likely to Exercise Despite Benefits
Saturday, June 18 – Recent research has found that despite the benefits, people using GLP-1s may be less likely to exercise. Image Credit: Fiordaliso/Getty Images
A recent study found that people taking a GLP-1 medication, like Ozempic or Wegovy, may be less likely to engage in regular exercise.
The study showed that, among people with obesity, daily step count and moderate-to-vigorous activity duration decreased after starting GLP-1 medication.
ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes
Saturday, June 18 – Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes
FRIDAY, June 12, 2026 — Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose…
GLP-1 Receptor Agonist Use Linked to Lower Incidence of Obesity-Associated Cancers
Friday, June 12 – For adults with obesity but without diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a significantly lower short-term incidence of obesity-associated cancers (OACs), according to a…
GLP-1 Receptor Agonist Use Linked to Lower Incidence of Obesity-Associated Cancers
THURSDAY, June 11, 2026 — For adults with obesity but without diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a significantly lower short-term incidence of obesity-associated cancers (OACs), according to a study…
Wegovy weight-loss pills to be available for patients in UK to buy
Friday, June 12 – Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription Patients in the UK will soon be able to buy the Wegovy weight-loss pill, the medicines regulator announced on Thursday.It is the first GLP-1 receptor agonist tablet for weight-loss to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), making the UK the third country to authorise the pills, behind the US and the United Arab Emirates. Continue reading…
Weight-loss drug Wegovy to be available in pill form in UK for first time
Friday, June 12 – Manufacturer Novo Nordisk says a daily tablet of the drug could be more convenient for some people than weekly injections.
VRB-103 shows potent and selective amylin receptor activity
Friday, June 12 – Researchers from Verdiva Bio Ltd. and collaborators recently presented preclinical data on VRB-103, an oral amylin analogue, comparing its profile with those of cagrilintide and eloralintide, two subcutaneously administered analogues currently in clinical development.
I Was Scammed Buying GLP-1s Online. I’m Not Alone
Thursday, June 11 – Customers have complained that a telehealth network selling compounded GLP-1s has been ripping them off—even after it had to pay $5 million to clients as part of a settlement with the US government.
New oral GLP-1 drug lowers blood sugar levels by 7% in people with type 2 diabetes
Thursday, June 11 – New oral GLP-1 drug lowers blood sugar levels by 7% in people with type 2 diabetes.